FDA chides Covidien on handling of surgical staple recall

June 27, 2012 by MassDevice staff

The FDA warns Covidien on missing documentation and delayed management of its recall of the Duet TRS surgical staples that were implicated in 13 patient injuries and 3 deaths.

Updated June 17, 2012, at 3:30 p.m. with comment from Covidien.

Covidien logo

The FDA wants Covidien (NYSE:COV) to defend its management of the recall of its Duet TRS surgical staples, which were pulled off the shelves after they were implicated in 13 patients injuries and 3 deaths.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.